FEBRUARY 06, 2024


Sable Bio, an innovative B2B software startup changing how biotech and pharma companies evaluate drug target safety for effective decision-making, today announced the successful closure of an oversubscribed £1.5 million pre-seed funding round, Episode 1 Ventures supported by Seedcamp, and ex-Deepmind, now Finster AI CEO Siddhant Jayakumar.

Sable facilitates broad access to specialist biomedical data, empowering scientists across different fields to make well-informed decisions about the safety of specific drug targets.

With unforeseen toxicity as a major driver of failure in drug discovery campaigns, Sable's approach offers substantial cost and time savings in drug development, delivering safer drugs to patients in need more rapidly.

Founded in 2023 and headquartered in London, Sable helps scientists identify and mitigate potential safety risks for drugs in development or about to enter the clinic, using a suite of state of the art techniques.

The company is currently seeking to establish partnerships with biotech, pharma, and healthtech companies, as well as academic collaborations.

The funding will enable building out a stellar team of scientists and engineers, enabling the refinement and enhancement of their core technological infrastructure, providing a solid and expansive foundation for their data capabilities

Josh Almond-Thynne - Co-founder:

We are really excited, this investment will help Sable Bio redefine drug safety assessment and change the ways actionable biomedical insights are generated. Working with leading investors Episode 1 and Seedcamp is enabling us to build an exceptional team and a platform to accelerate safer drug development for patients in need

Adam @ Episode 1:

Target safety remains a critical hurdle in the drug discovery process, and as two rockstar scientists, Alex and Josh are uniquely positioned to solve such a complex problem. The advent of LLMs is a monumental technological shift that will help Sable Bio unlock swathes of data previously inaccessible within the scientific literature, ultimately reducing the time-to-market and costs associated with clinical trials